Trials / Completed
CompletedNCT00781911
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Determine the 6-month progression free survival (PFS) rate associated with cixutumumab in combination with depot octreotide acetate (octreotide) in participants with metastatic neuroendocrine tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cixutumumab | Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. |
| DRUG | depot octreotide | Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen. |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2011-07-01
- Completion
- 2016-05-01
- First posted
- 2008-10-29
- Last updated
- 2019-09-20
- Results posted
- 2018-04-18
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00781911. Inclusion in this directory is not an endorsement.